BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marignani M, Marzano A, Begini P, Vitolo U, Luminari S, Levis A, Deli I, Gigante E, De Santis E, delle Fave G, Monarca B, Cox MC. Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. Leuk Lymphoma 2014;55:2564-71. [PMID: 24471911 DOI: 10.3109/10428194.2013.879712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Clerico M, Dogliotti I, Ghione P, Zilioli VR, Merli F, Botto B, Al Essa W, Battaglini M, Grimaldi D, Cervi L, Ragaini S, Ferrero S, Peri V, De Luca G, Marzano A, Cavallo F. HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. JPM 2022;12:285. [DOI: 10.3390/jpm12020285] [Reference Citation Analysis]
2 Zannella A, Marignani M, Begini P. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Viruses 2019;11:E858. [PMID: 31540124 DOI: 10.3390/v11090858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Salpini R, Battisti A, Colagrossi L, Di Carlo D, Fabeni L, Piermatteo L, Cerva C, Lichtner M, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Angelico M, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Svicher V. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. J Viral Hepat 2019;26:846-55. [PMID: 30974483 DOI: 10.1111/jvh.13101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Italian Association for the Study of the Liver (AISF). AISF position paper on HCV in immunocompromised patients. Dig Liver Dis 2019;51:10-23. [PMID: 30366813 DOI: 10.1016/j.dld.2018.09.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Yuen MF. Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy. Hepatol Int 2016;10:102-5. [PMID: 26739134 DOI: 10.1007/s12072-015-9694-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Leonard AN, Love BL, Norris LB, Siddiqui SK, Wallam MN, Bennett CL. Screening for viral hepatitis prior to rituximab chemotherapy. Ann Hematol 2016;95:27-33. [PMID: 26382277 DOI: 10.1007/s00277-015-2502-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
7 Teh BW, Slavin MA, Harrison SJ, Worth LJ. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Rev Anti Infect Ther 2015;13:1325-36. [PMID: 26489539 DOI: 10.1586/14787210.2015.1083858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
8 Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma 2015;56:1611-8. [PMID: 25248874 DOI: 10.3109/10428194.2014.964699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
9 Teh BW, Sasadeusz JJ. Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy. Leukemia & Lymphoma 2014;55:2426-7. [DOI: 10.3109/10428194.2014.918973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]